Mutual of America Capital Management LLC Raises Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Mutual of America Capital Management LLC increased its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 26.7% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,924 shares of the biopharmaceutical company’s stock after buying an additional 405 shares during the period. Mutual of America Capital Management LLC’s holdings in Alnylam Pharmaceuticals were worth $529,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the stock. Souders Financial Advisors grew its position in shares of Alnylam Pharmaceuticals by 1.0% during the 2nd quarter. Souders Financial Advisors now owns 3,512 shares of the biopharmaceutical company’s stock valued at $853,000 after acquiring an additional 36 shares during the period. Huntington National Bank grew its holdings in Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 45 shares during the period. Lindbrook Capital LLC increased its position in Alnylam Pharmaceuticals by 11.1% in the third quarter. Lindbrook Capital LLC now owns 570 shares of the biopharmaceutical company’s stock worth $157,000 after buying an additional 57 shares during the last quarter. V Square Quantitative Management LLC increased its position in Alnylam Pharmaceuticals by 21.9% in the second quarter. V Square Quantitative Management LLC now owns 334 shares of the biopharmaceutical company’s stock worth $81,000 after buying an additional 60 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC raised its stake in shares of Alnylam Pharmaceuticals by 54.2% in the second quarter. Allspring Global Investments Holdings LLC now owns 259 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 91 shares during the period. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Shares of Alnylam Pharmaceuticals stock opened at $253.35 on Wednesday. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39. The business’s 50 day simple moving average is $272.74 and its two-hundred day simple moving average is $239.37. The stock has a market capitalization of $32.68 billion, a P/E ratio of -96.70 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million for the quarter, compared to analyst estimates of $532.91 million. The firm’s revenue was down 33.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.15 earnings per share. Analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.21 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently weighed in on ALNY. The Goldman Sachs Group upgraded Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their price target for the stock from $198.00 to $370.00 in a research note on Friday, August 16th. Citigroup increased their target price on shares of Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Scotiabank boosted their price target on shares of Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the company a “sector outperform” rating in a research report on Friday, November 1st. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $220.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, October 11th. Finally, Chardan Capital reiterated a “buy” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and nineteen have issued a buy rating to the stock. According to MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $298.09.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.